Ad hoc: Evotec Announces Preliminary Second Quarter and First Half 2026 Results and Updates Full-Year 2026 Outlook
Evotec SE (NASDAQ: EVO) reported preliminary, unaudited Q2 and first-half 2026 results and updated its full-year outlook. It expects H1 2026 revenue of about €300.1m and adjusted EBITDA of about -€42.7m, with liquidity around €465.6m as of June 30. Full-year 2026 revenue guidance is €570-610m and adjusted EBITDA -€70 to -105m, down from prior €700-780m and €0-40m.
How this was made
The 30-second read
Why it matters
Guidance reset is the key trading input: first-half revenue and adjusted EBITDA are provided, and full-year revenue is lowered while adjusted EBITDA loss is widened versus prior guidance.
Market read
Traders can reprice expectations for 2026 revenue growth and margin trajectory immediately, with a clear catalyst date for final results.
What to watch
The release is explicitly preliminary and unaudited; the final Aug 13 numbers could narrow or reverse parts of the guidance gap, especially if working-capital or one-offs drive EBITDA.
Background
Evotec disclosed preliminary unaudited Q2 and H1 2026 figures and updated its full-year 2026 outlook, with final results scheduled for Aug 13, 2026.
Ticker impact
Evotec cut full-year 2026 revenue guidance to €570-610M and widened adjusted EBITDA loss to -€70 to -105M versus prior outlook.
Likely negative near-term repricing as traders adjust expectations for margins and cash burn ahead of the scheduled earnings release.
The article provides specific, time-sensitive guidance changes (revenue range down, EBITDA loss widened) plus liquidity level, which directly drives valuation and risk models.
Market effects
Biopharma services and drug development outsourcing sentiment may soften if peers face similar margin pressure, though this is company-specific guidance.
Could weigh on German small-to-mid cap biotech sentiment and Hamburg-listed biotech peers via read-across on cash burn and profitability.
Limited broader impact beyond European biotech services expectations unless similar guidance resets appear across the sector.
Counterpoint
Liquidity of about €465.6M as of June 30 may reduce immediate solvency concerns, limiting downside if investors focus on runway rather than EBITDA losses.
Key entities
- companyEvotec SE
Announced preliminary Q2 and H1 2026 results and updated full-year 2026 revenue and adjusted EBITDA outlook.
- listingNASDAQ: EVO
US listing referenced in the disclosure, indicating the ticker subject for US traders.
